Xiang-Qian

Xiangqian Biotechnology is a China-based biopharmaceutical company specializing in the development of targeted protein degradation (TPD) therapies. Utilizing its proprietary Degradon platform, the company focuses on creating next-generation Proteolysis-Targeting Chimeras (PROTACs) and molecular glues to address previously undruggable targets in oncology. The company's research and development efforts are primarily directed toward hormone-driven cancers, such as prostate and breast cancer, as well as hematological malignancies. Xiangqian Biotechnology aims to overcome resistance mechanisms associated with traditional small molecule inhibitors by leveraging the body's natural protein disposal system.